4idj: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==S.Aureus a-hemolysin monomer in complex with Fab== | ==S.Aureus a-hemolysin monomer in complex with Fab== | ||
<StructureSection load='4idj' size='340' side='right' caption='[[4idj]], [[Resolution|resolution]] 3.36Å' scene=''> | <StructureSection load='4idj' size='340' side='right'caption='[[4idj]], [[Resolution|resolution]] 3.36Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4idj]] is a 3 chain structure with sequence from [ | <table><tr><td colspan='2'>[[4idj]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/"micrococcus_aureus"_(rosenbach_1884)_zopf_1885 "micrococcus aureus" (rosenbach 1884) zopf 1885] and [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4IDJ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4IDJ FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">hla, hly ([ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">hla, hly ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=1280 "Micrococcus aureus" (Rosenbach 1884) Zopf 1885])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4idj FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4idj OCA], [https://pdbe.org/4idj PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4idj RCSB], [https://www.ebi.ac.uk/pdbsum/4idj PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4idj ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[[ | [[https://www.uniprot.org/uniprot/HLA_STAAU HLA_STAAU]] Alpha-toxin binds to the membrane of eukaryotic cells resulting in the release of low-molecular weight molecules and leading to an eventual osmotic lysis. Heptamer oligomerization and pore formation is required for lytic activity. | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 19: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 4idj" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 4idj" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Hemolysin 3D structures|Hemolysin 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
| Line 24: | Line 27: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | [[Category: Human]] | ||
[[Category: Large Structures]] | |||
[[Category: Strop, P]] | [[Category: Strop, P]] | ||
[[Category: Cytolytic protein]] | [[Category: Cytolytic protein]] | ||
Revision as of 12:22, 26 May 2021
S.Aureus a-hemolysin monomer in complex with FabS.Aureus a-hemolysin monomer in complex with Fab
Structural highlights
Function[HLA_STAAU] Alpha-toxin binds to the membrane of eukaryotic cells resulting in the release of low-molecular weight molecules and leading to an eventual osmotic lysis. Heptamer oligomerization and pore formation is required for lytic activity. Publication Abstract from PubMedThe emergence and spread of multi-drug-resistant strains of Staphylococcus aureus in hospitals and in the community emphasize the urgency for the development of novel therapeutic interventions. Our approach was to evaluate the potential of harnessing the human immune system to guide the development of novel therapeutics. We explored the role of preexisting antibodies against S. aureus alpha-hemolysin in the serum of human individuals by isolating and characterizing one antibody with a remarkably high affinity to alpha-hemolysin. The antibody provided protection in S. aureus pneumonia, skin, and bacteremia mouse models of infection and also showed therapeutic efficacy when dosed up to 18 h post-infection in the pneumonia model. Additionally, in pneumonia and bacteremia animal models, the therapeutic efficacy of the alpha-hemolysin antibody appeared additive to the antibiotic linezolid. To better understand the mechanism of action of this isolated antibody, we solved the crystal structure of the alpha-hemolysin:antibody complex. To our knowledge, this is the first report of the crystal structure of the alpha-hemolysin monomer. The structure of the complex shows that the antibody binds alpha-hemolysin between the cap and the rim domains. In combination with biochemical data, the structure suggests that the antibody neutralizes the activity of the toxin by preventing binding to the plasma membrane of susceptible host cells. The data presented here suggest that protective antibodies directed against S. aureus molecules exist in some individuals and that such antibodies have a therapeutic potential either alone or in combination with antibiotics. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin.,Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, Bee C, Wu S, Pham A, Zeng Z, Pons J, Rajpal A, Shelton D J Mol Biol. 2013 May 27;425(10):1641-54. doi: 10.1016/j.jmb.2013.02.008. Epub, 2013 Feb 13. PMID:23416200[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||